A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.

Also called NCT01149421

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 755 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01149421
  • CTRI CTRI/2010/091/001444
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Canada, Czechia, Denmark, India, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01149421. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2015-02-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2189265
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01149421
Content hash
e51e86ee85f94146b07588b45d6c9e57249f2269139e4746b77e695ea0c4c737